Bioanalytical services

  • Bioanalytical services can be used in preclinical research, in support of in vivo studies and during clinical development.
  • Learn more about our offering within Charles River.

Our expertise in bioanalytical methods benefits early stage screens for hit-to-lead, lead identification and lead optimisation programmes - we can confirm your drug's effect and mechanism of action. By working with clients in the early stages of their programmes, we can also identify the most informative clinical biomarkers to user in early stage clinical trials.

Please get in touch with us to discuss how our bioanalytical services can support your preclinical and clinical programmes. Some examples are shown below.

Bespoke screening assay development

With our state-of-the-art facilities and expertise in immunology, infection, and cell biology, we will work with you to tailor our capabilities to suit your research programme.

Asset 2

Spotlight assay

KWS BioTest profile the effects of your compounds on platelet activation using fresh blood from donors or animals.

Asset 1
Asset 2

Our bioanalytical team measure cytokine responses in order to determine compound potency.

Asset 1

Mechanism of action confirmation

As your lead compounds move into pharmacology models, we will assess efficacy, but also measure suitable PD markers in order to confirm mechanism of action.

Spotlight assay 

KWS BioTest uses multiplex analysis in order to measure changes in the nature of the immune response to autoantigens resulting from disease modulation using novel treatments.

We look forward to speaking with you about our full range of bioanalytical services.

Our bioanalytical team measure cytokine responses in order to determine compound potency.

From small sample programmes to full blown clinical sample analysis KWS BioTest's bioanalytical group have the experience and technology to provide the data required.